The European Laboratory Research & Innovation Group (ELRIG) UK has revealed the keynote speakers for its flagship conference, Drug Discovery 2024. The event, scheduled for 2-3 October at ExCeL London, will feature presentations from two distinguished scientists in the field of pharmaceutical research and development.
Researchers at the Arc Institute have unveiled a groundbreaking genetic engineering tool called the bridge recombinase mechanism, offering unprecedented precision in DNA recombination and rearrangement. The study, published in Nature [1], details the discovery of the first DNA recombinase that utilises a non-coding RNA for sequence-specific selection of target and donor DNA molecules.
Researchers at the Fraunhofer Institute for Biomedical Engineering IBMT have developed innovative solutions for the production and preservation of human induced pluripotent stem (hiPS) cells, potentially revolutionising drug discovery and toxicity testing processes.
A new lab assay developed by researchers at Fred Hutch Cancer Center in Seattle could make diagnosis and treatment of small-cell lung cancer and non-small cell lung cancer easier.
The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organisation for the drug discovery community, is partnering with SRG, leaders in life science recruitment, to support the advancement of science professionals in their careers.
Teva UK and Closed Loop Medicine will collaborate to advance the development of personalised medicine. Under the agreement, Closed Loop Medicine – a leading TechBio company – and Teva UK – a pharmaceutical company, will investigate opportunities to use Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform which aims to advance […]
Novo Nordisk will acquire Cardior Pharmaceuticals for up to €1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
Preci, a biotechnology company advancing patient-derived cell models to bridge the gap between preclinical testing and clinical trials, and Biopredic International, a biotechnology company specializing in the design and manufacture of human and animal in vitro assay systems, will collaborate on for the production of pooled suspension human hepatocytes.
Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, will collaborate with Oncocyte Corporation, a precision diagnostics company, to develop and commercialize transplant monitoring products using Bio-Rad’s Droplet Digital PCR (ddPCR) instruments and reagents.
In the wake of recent global outbreaks, people around the world were alerted to the importance of proper biosafety precautions, and the role they can play in stopping public health catastrophes.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
